AIM
SRRA

Acrospire Investment Management’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Acrospire Investment Management’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-290
Closed -$18K – 2654
2017
Q1 		$18K Buy
290
+160
+123% +$9.3K 0.01% 1675
2016
Q4 		$8K Buy
+130
New +$8.11K ﹤0.01% 1997

Other funds holding SRRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Acrospire Investment Management's SRRA Position: Q2 2017 in Review

Acrospire Investment Management sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2017, closing a stake of 290 shares — an estimated $18K sold.

Acrospire Investment Management first reported a position in SRRA in Q4 2016 and held it in 2 quarters. The position peaked at $18K in Q1 2017. 40 funds tracked by Wall St. Rank hold SRRA as of Q2 2017.

  • Acrospire Investment Management reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 290 Sierra Oncology, Inc. Common Stock shares in Q2 2017, an estimated $18K.
  • Acrospire Investment Management first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Sierra Oncology, Inc. Common Stock position peaked at $18K in Q1 2017.
  • 40 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.